Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

NCT02191228 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Insufficiency

Interventions

DRUG: Linagliptin - single dose
DRUG: Linagliptin - Multiple dose

Sponsor

Boehringer Ingelheim